Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus SNRI in major depressive disorder
ISRCTN96725312Phase 3Completed
- Sponsor
- Servier
- Start
- Apr 2009
- Modality
- Small Molecules
01
Overview
Phase 3 trial of agomelatine and venlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Hamilton Rating Scale for Depression total score. Started Apr 2009; status: completed.
02
Drugs
agomelatinevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN96725312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN96725312.